CN105232531A - Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers - Google Patents
Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers Download PDFInfo
- Publication number
- CN105232531A CN105232531A CN201510752769.3A CN201510752769A CN105232531A CN 105232531 A CN105232531 A CN 105232531A CN 201510752769 A CN201510752769 A CN 201510752769A CN 105232531 A CN105232531 A CN 105232531A
- Authority
- CN
- China
- Prior art keywords
- penifulvina
- treating
- penifulvin
- day
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the application of Penifulvin A in preparing drugs for treating or preventing dental ulcers. The application of Penifulvin A in preparing drugs for treating or preventing dental ulcers is disclosed for the first time. Due to the fact that a novel framework type is adopted and Penifulvin A has surprisingly strong activity in treating dental ulcers, the possibility that revelation is given by other compounds is avoided, prominent substantive features are realized, and a remarkable progress is made in treating dental ulcers.
Description
Technical field
The present invention relates to the novelty teabag of compound PenifulvinA, particularly relate to the application of PenifulvinA in preparation treatment or preventing canker sore medicine.
Background technology
Recurrent oral ulceration is modal disease in diseases of oral mucosa.The first place of prevalence office diseases of oral mucosa.Sircus (1975) investigates 1587 people, and prevalence is 20%.As can be seen here, oral ulcer patient is a very huge colony.The cause of disease of recurrent oral ulceration is complicated, still indefinite so far, may be relevant with the factor such as the endocrine regulation of viral infection, bacteriological infection and body, immune dysfunction.
The primary treatment measure of oral ulcer comprises topical therapeutic and whole body therapeutic, and because topical therapeutic toxic and side effects is lower, the people therefore obtaining people can.Although the buccal tablets that the local that occurs in recent years uses carries, easy to use, mouthfeel and compliance better, as lysozyme buccal tablet, watermelon crystal buccal tablet, cydiodine etc., these medicines emphasize particularly on different fields in sterilization, antiinflammatory, pain relieving etc.
The compound PenifulvinA that the present invention relates to is one and delivers (DipenduDas in 2014, etal., AnApproachtoaBislactoneSkeleton:AScalableTotalSynthesiso f (±)-PenifulvinA.OrganicLetters, 2014, 16, noval chemical compound 2618-2621.), this compound has brand-new framework types, current purposes only relates to parasite killing (DipenduDas, etal., AnApproachtoaBislactoneSkeleton:AScalableTotalSynthesiso f (±)-PenifulvinA.OrganicLetters, 2014, 16, 2618-2621.), the purposes of the PenifulvinA that the present invention relates in preparation treatment or preventing canker sore medicine is belonged to first public, owing to belonging to brand-new structure type, and its for treatment or preventing canker sore active unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, to be used for the treatment of or preventing canker sore obviously has significant progress simultaneously.
Summary of the invention
The object of the invention is to not find that it has the present situation of the report for the treatment of or preventing canker sore according in existing PenifulvinA research, provide the application of PenifulvinA in preparation treatment or preventing canker sore medicine.
Described compound PenifulvinA structure is as shown in formula I:
The purposes of the PenifulvinA that the present invention relates in preparation treatment or preventing canker sore medicine belongs to first public, because framework types belongs to brand-new framework types, and its treatment or preventing canker sore active unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, to be used for the treatment of or preventing canker sore obviously has significant progress simultaneously.
Detailed description of the invention
The preparation method of compound PenifulvinA involved in the present invention is see document (DipenduDas, etal., AnApproachtoaBislactoneSkeleton:AScalableTotalSynthesiso f (±)-PenifulvinA.OrganicLetters, 2014,16,2618-2621.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound PenifulvinA tablet involved in the present invention:
Get 20 g of compound PenifulvinA and add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound PenifulvinA capsule involved in the present invention:
Get 20 g of compound PenifulvinA add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
The experimental study of test example 1:PenifulvinA anti-oral ulcer
1, test objective: manufacture Oral ulcer model with phenol, gives the PenifulvinA of Oral ulcer model rat certain number of times every day, and whether observe PenifulvinA has the effect reducing ulcer.
2, test medicine and reagent
Cydiodine (Beijing Sihuan Medicine Science and Technology Co., Ltd); Phenol animal: Wistar rat, male, body weight 240 ~ 280g
3, test method
Get rat 50, male, body weight 240 ~ 280g, 10% chloral hydrate anesthesia, dosage: 0.35ml/100g, after anesthesia, plastic dropper (internal diameter: the 3mm) lower end of 90% phenol cotton balls being flat on rats with left bicker is about on the cheek film at 1mm place, calcination 30min, namely sees the white infringement of this place about 3mm.Divide into groups immediately after 24 hours, often organize 10, divide 5 groups, i.e. model group (adjuvant 4 times/day, not drug containing); PenifulvinA high dose group (4 times/day, 0.5mg/ time); Dosage (4 times/day, 0.1mg/ time) in PenifulvinA; PenifulvinA low dose group (4 times/day, 0.02mg/ time); Positive controls: cydiodine group (4 times/day, 0.5mg/ time).PenifulvinA and cydiodine buccal tablet pulverize before use, administration is degree of being with flap coverage.Successive administration 5 days, after the front and each administration of administration, next day observes ulcer area size (diameter in ulcer) and ulcer healing situation (being considered as healing without macroscopic ulcer), and first administration is recorded as 1,2,3,4,5,6 day respectively to last administration.Ulcer area size t checks, and ulcer healing rate X2 checks.
4, result of the test
Ulcer area compares (table 1): PenifulvinA high dose group compares with model group, within the 3rd day, plays off-test from administration, and corresponding every day compares significant difference; Cydiodine group compares with model group, within the 3rd day, plays off-test from administration, and corresponding every day compares significant difference; In PenifulvinA, dosage group compares with model group, within the 3rd day, plays off-test from administration, and corresponding every day compares significant difference; PenifulvinA low dose group compares with model group, within the 5th day, plays off-test from administration, and corresponding every day compares significant difference; In PenifulvinA, dosage group compares with cydiodine group, within the 1st day, plays off-test from administration, and corresponding every day compares significant difference.
Table 1 is on the impact of rat ulcer area
Note: compare with model group, * p<0.05, * p<0.01.
Healing rate (table 2): model group and PenifulvinA low dose group play off-test on the 1st day from administration, and ulcer does not heal; And PenifulvinA high dose group was from administration the 4th day, just there is ulcer healing, to off-test, reach 90%; Cydiodine group, from administration the 4th day, has ulcer healing, to off-test, reaches 60%; In PenifulvinA, dosage group was from administration the 5th day, had ulcer healing, to off-test, reached 40%.
Table 2 is on the impact of rat ulcer healing time
Note: compare with model group, * p<0.05, * p<0.01.
5, conclusion
PenifulvinA has the effect obviously promoting oral ulcer healing.
Claims (1)
- The application of 1.PenifulvinA in treatment or preventing canker sore medicine, described compound PenifulvinA structure is as shown in formula I:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510752769.3A CN105232531A (en) | 2015-11-09 | 2015-11-09 | Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510752769.3A CN105232531A (en) | 2015-11-09 | 2015-11-09 | Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105232531A true CN105232531A (en) | 2016-01-13 |
Family
ID=55030533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510752769.3A Pending CN105232531A (en) | 2015-11-09 | 2015-11-09 | Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105232531A (en) |
-
2015
- 2015-11-09 CN CN201510752769.3A patent/CN105232531A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103585147B (en) | Application of Nitrosporeusines A in preparation of oral ulcer treatment or prevention medicines | |
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN107501435A (en) | The extracting method of pachymaran and its application | |
| CN103356653B (en) | The application of Chukrasone A in preparation treatment or preventing canker sore medicine | |
| CN106344555A (en) | Application of Fistulains B in drugs for dental ulcer prevention or treatment | |
| CN105232531A (en) | Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers | |
| CN103599104B (en) | Application of Caesanines D in drug for treating or preventing dental ulcer | |
| CN103479624B (en) | Application of Racemosins A in preparation of oral ulcer treatment or prevention medicines | |
| CN103505464B (en) | The application of Phyllanthoid A in preparation treatment or preventing canker sore medicine | |
| CN103638005B (en) | The application of Hippolachnin A in treatment or preventing canker sore medicine | |
| CN105412109A (en) | Application of Biscarpamontamine B in preparing drugs for treating or preventing dental ulcers | |
| CN105287543A (en) | Application of strynuxlines B to prepare medicines treating or preventing oral ulcer | |
| CN105147676A (en) | Medicine for preventing or treating dental ulcer | |
| CN105434428A (en) | Applications of Volvalerelactones B in preparing drugs used for treating or preventing dental ulcer | |
| CN102872056B (en) | Application of Gypensapogenin A to preparing drugs for treating or preventing canker sores | |
| CN102872060B (en) | Application of Gypensapogenin B to preparing drugs for treating or preventing canker sores | |
| CN106491621A (en) | Friedolanostanes is preparing treatment or the application in preventing canker sore medicine | |
| CN102988382B (en) | Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer | |
| CN103263423A (en) | Application of myriberine A in preparation of medicaments for treating or preventing canker sores | |
| CN106265638A (en) | Linderolide H application in preparation treatment or preventing canker sore medicine | |
| CN106619604A (en) | Medicine for treating or preventing dental ulcer, and application of medicine | |
| CN103961654B (en) | A kind of White staphylococcus sheet and preparation method thereof | |
| CN103462998A (en) | Application of Neonectrolide A in preparing medicament for treating or preventing dental ulcer | |
| CN103393655A (en) | Application of Sarcaboside B to medicament for treatment and prevention of oral ulcer | |
| CN103127077A (en) | Application of Aphanamixoid A to dental ulcer treatment or prevention medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160113 |